MEDICENNA THERAPEUTICS CORP

Medic​enna Therapeutics (MDNA.TO) shows steady gains as investors eye its CNS & urologic oncology pipeline—key market insights & growth outlook.

Medicenna Therapeutics (MDNA.TO) jumps 5.13% in a 24‑hr trade, outpacing peers and signaling fresh optimism for its CNS cancer immuno‑therapy pipeline.

Medicenna Therapeutics drops 4.9%, falling below its 200‑day SMA as investors await clinical milestones. Small‑cap biotech struggles amid market volatility.